12:00 AM
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ocriplasmin regulatory update

FDA approved a BLA from ThromboGenics for Jetrea ocriplasmin to treat symptomatic vitreomacular adhesion (VMA). The company plans to launch...

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >